Product Description: BOLD-100 (NKP-1339; IT-139) is the first-in-class ruthenium-based anticancer agent in development against solid cancer with limited side effects. BOLD-100 induces G2/M cell cycle arrest, blockage of DNA synthesis, and induction of apoptosis via the mitochondrial pathway. BOLD-100 has a high tumor targeting potential, strongly binds to serum proteins such as albumin and transferrin and activates in the reductive tumor milieu[1].
Applications: Cancer-Kinase/protease
Formula: C14H12Cl4N4NaRu
References: [1]Robert Trondl, et al. NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application. Chemical Science. Chemical Science/[2]Heffeter P, et al. The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. Eur J Cancer. 2013 Oct;49(15):3366-75.
CAS Number: 197723-00-5
Molecular Weight: 502.14
Compound Purity: 95.20
Research Area: Cancer
Solubility: DMSO : ≥ 59 mg/mL
Target: Apoptosis;DNA/RNA Synthesis
English
Deutsch
